EndoBarrier™ Implantation Rapidly Improves Insulin Sensitivity in Obese Individuals with Type 2 Diabetes Mellitus

The EndoBarrier (TM) medical device is a duodenal-jejunal bypass liner designed to mimic the effects of gastric bypass surgery to induce weight loss and glycaemic improvement. In this study, 10 participants with type 2 diabetes mellitus (T2DM), a mean body mass index (BMI) of 43.3 +/- 5.0 (kg/m(2)) and a mean glycated haemoglobin A1c (HbA1c) of 60.6 +/- 8.6 mmol/mol were examined at baseline (before implantation of EndoBarrier (TM)), 4 weeks after implantation, at 36 weeks (right before explantation) and 24 weeks after the removal of the device to explore the short and long-term effects on glucose metabolism. Besides a significant reduction in body weight and fat mass, EndoBarrier (TM) treatment significantly improved insulin sensitivity during Botnia clamp investigations after four weeks of implantation. The beneficial effects decreased over time but remained significant 24 weeks after removal of the device.

Automated summary

The study showed that EndoBarrier (TM) had significant effects on weight loss, reduction of fat mass, and improvement of insulin sensitivity, which remained after the removal of the device.